BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Acquired by Raymond James & Associates

Raymond James & Associates increased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 4.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 139,997 shares of the medical equipment provider’s stock after acquiring an additional 5,803 shares during the quarter. Raymond James & Associates owned approximately 0.30% of BioLife Solutions worth $3,506,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. 1620 Investment Advisors Inc. acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at $35,000. Isthmus Partners LLC increased its holdings in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 42,265 shares during the period. GAMMA Investing LLC increased its holdings in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after acquiring an additional 748 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at $122,000. Finally, Arizona State Retirement System acquired a new position in shares of BioLife Solutions in the 2nd quarter valued at $217,000. 93.24% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the sale, the executive now directly owns 114,773 shares in the company, valued at $2,883,097.76. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total value of $239,000.00. Following the sale, the executive vice president now directly owns 317,716 shares in the company, valued at $7,593,412.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CRO Garrie Richardson sold 3,070 shares of the business’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the completion of the sale, the executive now owns 114,773 shares in the company, valued at $2,883,097.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 27,044 shares of company stock worth $645,105. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Price Performance

Shares of NASDAQ BLFS opened at $24.07 on Monday. The firm has a market capitalization of $1.11 billion, a P/E ratio of -14.24 and a beta of 1.88. BioLife Solutions, Inc. has a one year low of $9.92 and a one year high of $26.73. The company’s fifty day moving average is $24.04 and its two-hundred day moving average is $22.21. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.81 and a current ratio of 2.86.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.08. The company had revenue of $28.33 million for the quarter, compared to analyst estimates of $23.80 million. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. Analysts forecast that BioLife Solutions, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

BLFS has been the topic of a number of analyst reports. HC Wainwright initiated coverage on shares of BioLife Solutions in a research report on Monday, September 30th. They issued a “buy” rating and a $29.00 price objective on the stock. TD Cowen lifted their price objective on shares of BioLife Solutions from $20.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, July 17th. Northland Securities lifted their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Finally, Craig Hallum lifted their price objective on shares of BioLife Solutions from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, August 12th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, BioLife Solutions has an average rating of “Moderate Buy” and a consensus target price of $26.67.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.